Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
ISS-focused company reports $2.9 million second-quarter loss
September 8th, 2004
Dynavax Technologies Corp. (DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases, reported financial results for the quarter and 6 months ended June 30, 2004. Dynavax reported a net loss of $2.9 million for the quarter ended June 30, 2004, or $0.12 per basic and diluted share, compared to a net loss of $4.0 million, or $2.23 per basic and diluted share for the same period in 2003. As of June 30, 2004, cash and cash equivalents totaled $74.0 million. Revenue for the second quarter ended June 30, 2004 was $5.5...
Source: Vaccine Weekly (2004-09-08)
|
